Blair Gottscho
VP Operations
HCPs and patients expect more. Personalisation, authenticity and purpose are our new mantras. To create real relationships with HCPs and patients you can’t continue on the same path. Data must become the lifeblood fuelling every engagement decision. Valuable, educational content must be your communication device. And delivery must be digitally-enabled, delivering exceptional experiences, rivalling those of the tech giants…now more than ever.
“eyeforpharma [now Reuters Events Pharma] has been an excellent partner for us in helping to build our pipeline and nurture relationships with decision-makers in the industry”
Marcus West, CEO, 60 Seconds
This webinar showed attendees what a ‘modern, unified, intelligent backbone’ could provide for life sciences companies – where an integration between content, data models, business processes and analytics could mean we transcend the level of customer interaction and engagement that we have achieved so far. And finally hit the twin goals of better experience and more intelligent, personalised outreach.
TARGET JOB TITLES: Managers, Director and VPs of Marketing, Sales, Commercial Excellence, Data & Analytics, Customer Experience, Customer Engagement
TARGET COMPANIES:
Medical Affairs has risen from zero to hero, fast becoming the most vital part of the pharma organisation. The pressure is now on, as medical teams must fuel stakeholder engagement, build real partnerships, perfect value demonstration and orchestrate cross-company evidence generation – all whilst ensuring that patient value is the guiding light. It’s time for Medical to understand its true role and ensure its position at the center of future success of the company.
“eyeforpharma [now Reuters Events Pharma] has been an excellent partner for us in helping to build our pipeline and nurture relationships with decision-makers in the industry”
Marcus West, CEO, 60 Seconds
Within pharma companies, medical departments have steadily risen to prominence. As well as having a grip on key scientific, medical and compliance issues, medical staff must engage more deeply with customers while cultivating a new appreciation of the company’s commercial and strategic challenges. In all these endeavors, medical affairs must work with new types of data being generated from a multiplicity of sources inside and outside the organization.
“Pharma is several years behind the curve when innovating in digital areas other than medicine, and medical affairs is even further behind”
Christopher Keenan, Head of Medical Customer Engagement at BMS
TARGET JOB TITLES: Managers, Director and VPs of Medical Affairs, Digital and IT
TARGET COMPANIES:
“Pharma is several years behind the curve when innovating in digital areas other than medicine, and medical affairs is even further behind”
Christopher Keenan, Head of Medical Customer Engagement at BMS
From clinical trials through to support programmes and strategic decision-making, we know that incorporating patients into design has untold benefits. But today’s efforts are mostly incremental adjustments of existing processes rather than wholesale change. Unfortunately, that means we are not delivering at the pace patients require.
“eyeforpharma [now Reuters Events Pharma] has been an excellent partner for us in helping to build our pipeline and nurture relationships with decision-makers in the industry”
Marcus West, CEO, 60 Seconds
Behavioral science, combined with effective use of technology, provides a holistic, practical approach to patient engagement – addressing not just the clinical but also the psychosocial aspects of living with a condition. And when done well, it empowers patients to self-manage their own healthcare and build a new, positive journey. This webinar showed attendees how to:
“Delivering webinars around helping pharma to integrate patient insights is always very rewarding given how much we can see it helps the industry deliver more value for patients”
Josh Bramwell, Head of Europe, Reuters Events Pharma
TARGET JOB TITLES: Managers, Director and VPs of Medical Affairs, Patient Engagement, Patient Insights, Patient Experience.
TARGET COMPANIES:
SPEAKERS : Alexion, Micromass, Novartis and Ashfield
“Delivering webinars around helping pharma to integrate patient insights is always very rewarding given how much we can see it helps the industry deliver more value for patients”
Josh Bramwell, Head of Europe, Reuters Events Pharma
Now, more than ever, is the time for real-world evidence (RWE) to come out of the shadows. You may have been saying this for years. But as we enter a new normal – a healthcare environment awakened to the remote, digital and data – RWE is increasing in importance. You will also know, achieving our real-world ambitions comes with a great many challenges. And whether they’re infrastructure, capability, cultural or technology related - those challenges, no matter how great the current need, still exist and must be overcome before regulatory and access decision-makers can fully embrace our ambitions. That’s where you step in...
“eyeforpharma [now Reuters Events Pharma] has been an excellent partner for us in helping to build our pipeline and nurture relationships with decision-makers in the industry”
Marcus West, CEO, 60 Seconds
Real-world evidence (RWE) has had increased impact on the development and commercialization of new treatments. Now, the FDA, prompted by the 21st Century Cures Act, is engaged in a multi-year process to determine exactly how RWE can augment or even substitute randomized clinical trials (RCTs), to get the right treatment to the right patient faster and safely. As part of this commitment, Brigham and Women’s Hospital, Harvard Medical School, and Aetion have collaborated to launch RCT DUPLICATE, an FDA-funded demonstration project in which real-world data is used to replicate the findings of 30 completed Phase III and IV randomized control trials, and to predict the results of seven ongoing Phase IV trials. The project aims to identify when, where, and how RWE sourced from healthcare databases can answer key questions in drug development. This webinar (a) shares interim findings and (b) determines how pharma can apply the study’s interim findings to launch a new era in which pharma can have confidence in scientifically valid real-world evidence.
“Bringing cutting-edge research to this webinar helped it attract a lot of interest from a very targeted pharma audience.”
James Mackintosh, Head of Product, Reuters Events Pharma
TARGET JOB TITLES: Managers, Director and VPs of Epidemiology, RWE, HEOR, Scientific, Market Access, Medical Affairs.
TARGET COMPANIES:
“Bringing cutting-edge research to this webinar helped it attract a lot of interest from a very targeted pharma audience.”
James Mackintosh, Head of Product, Reuters Events Pharma
Regulators, payers and HTAs are changing. Clear themes are emerging, including harmonisation, increasingly bespoke agreements and the consideration of new forms of evidence. But these are not solutions - health systems remain close to breaking point, with industry and payers often failing to reach agreement on value and affordability. We must now harness maturing RWE and digital capabilities to advance access approaches and create a more affordable, value-driven system. Pharma leaderships from across functional areas need to come together with key market access authorities and pharma market access experts to accelerate harmonisation and spark our next evolutionary leap forward.
“eyeforpharma [now Reuters Events Pharma] has been an excellent partner for us in helping to build our pipeline and nurture relationships with decision-makers in the industry”
Marcus West, CEO, 60 Seconds
Real-world evidence (RWE) has had increased impact on the development and commercialization of new treatments. Now, the FDA, prompted by the 21st Century Cures Act, is engaged in a multi-year process to determine exactly how RWE can augment or even substitute randomized clinical trials (RCTs), to get the right treatment to the right patient faster and safely. As part of this commitment, Brigham and Women’s Hospital, Harvard Medical School, and Aetion have collaborated to launch RCT DUPLICATE, an FDA-funded demonstration project in which real-world data is used to replicate the findings of 30 completed Phase III and IV randomized control trials, and to predict the results of seven ongoing Phase IV trials. The project aims to identify when, where, and how RWE sourced from healthcare databases can answer key questions in drug development. This webinar (a) shares interim findings and (b) determines how pharma can apply the study’s interim findings to launch a new era in which pharma can have confidence in scientifically valid real-world evidence.
“Bringing cutting-edge research to this webinar helped it attract a lot of interest from a very targeted pharma audience.”
James Mackintosh, Head of Product, Reuters Events Pharma
TARGET JOB TITLES: Managers, Director and VPs of Epidemiology, RWE, HEOR, Scientific, Market Access, Medical Affairs.
TARGET COMPANIES:
“Bringing cutting-edge research to this webinar helped it attract a lot of interest from a very targeted pharma audience.”
James Mackintosh, Head of Product, Reuters Events Pharma
If you ask pharma’s c-suite where to look for real innovation is, for the first time in a very long time, their answer is “clinical”. These seeds of change, driven by patient centric and digital transformations, have been given rocket fuel. The COVID-19 pandemic has created an environment where fear of failure is no longer an option. Pharma must digitally transform its recruitment and retention, data and evidence generation strategies. While regulators must embrace new types of trial, be it synthetic, patient-preferred, siteless or virtual. Resistance to innovation is futile.
“eyeforpharma [now Reuters Events Pharma] has been an excellent partner for us in helping to build our pipeline and nurture relationships with decision-makers in the industry”
Marcus West, CEO, 60 Seconds
Behavioral science, combined with effective use of technology, provides a holistic, practical approach to patient engagement – addressing not just the clinical but also the psychosocial aspects of living with a condition. And when done well, it empowers patients to self-manage their own healthcare and build a new, positive journey. This webinar showed attendees how to:
“It was clear this topic was an important one for pharma with a very good number of registrants for a relatively niche topic. Digital endpoints are a topic we will be delivering more content on, in the future”
Blair Gottscho, Managing Director, Reuters Events Pharma
TARGET JOB TITLES: Managers, Director and VPs of Medical Affairs, Patient Engagement, Patient Insights, Patient Experience.
TARGET COMPANIES:
SPEAKERS : Alexion, Micromass, Novartis and Ashfield
“It was clear this topic was an important one for pharma with a very good number of registrants for a relatively niche topic. Digital endpoints are a topic we will be delivering more content on, in the future”
Blair Gottscho, Managing Director, Reuters Events Pharma
There is a paradigm shift in healthcare. Uniting CEOs, innovators, disruptors and policy makers, Reuters Events Healthcare sets the roadmap for a system of full access and complete health equality. As the world looks to the healthcare industry for guidance, this is where its leaders come to set the agenda and change lives.
“eyeforpharma [now Reuters Events Pharma] has been an excellent partner for us in helping to build our pipeline and nurture relationships with decision-makers in the industry”
Marcus West, CEO, 60 Seconds
Make the point of care anywhere with remote health
Beyond Patient Centricity: The Consumerization of Health
Innovate Out of Crisis to Drive Affordability and Widen Access
How AI is Radically Improving the Delivery of Care
Reuters Events Healthcare: Virtual Forum
Virtual Roundtables
We’re here to help support your marketing objectives and we are keen to align you with the right content!
VP Operations
Director of Business Development